ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026
Neonatal Surveillance Gaps in Maternal Graves' Disease: Findings From a Queensland Maternity Hospital.
Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraves' disease presents unique challenges in pregnancy due to the risk of neonatal morbidity and mortality from maternal TSH Receptor antibodies (TRAb). A maternity hospital in Queensland has implemented a policy to identify at-risk neonates and facilitate follow-up, including cord blood TRAb, thyroid function tests (TFTs), and clinic appointments.
aimsTo evaluate current neonatal follow-up practices for mothers with Graves' disease, assess missed opportunities for biochemical testing and propose recommendations to improve clinical care. MATERIALS AND
methodsThis retrospective audit covered deliveries between 1st January 2018 to 31st December 2022. Baseline characteristics and follow-up were summarised by frequency and percentage. Maternal records were reviewed for demographic data, ultrasound follow up, TRAb titres, TFTs, and treatment details. Corresponding neonatal charts were then reviewed for cord blood TRAb levels, TFTs on days 3-5 and days 10-14, and phone clinic appointments. Neonatal testing was indicated if the mother was positive for thyroid stimulating immunoglobulin (TSI) or if TRAb titres were > 3 times the upper limit of normal.
resultsData from 70 mothers with active or previously treated Graves' disease were analysed; 18 pregnancies met criteria for neonatal testing. Compliance with recommended testing was suboptimal, with variable adherence to TFT testing and only 10% undergoing cord blood TRAb measurement.
conclusionThis audit highlights the importance of standardised protocols and ongoing education to optimise neonatal follow-up and improve outcomes for neonates born to mothers with Graves' disease. Recommendations for education, improved documentation and policy updates have been provided with the aim for further audits to ensure ongoing quality improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.